Pharmaceutical intermediates
Treprostinil Intermediates
7 pharmaceutical intermediates for Treprostinil. Indication: Interstitial Lung Disease ; Pulmonary Hypertension; Pulmonary Arterial Hypertension.
About Treprostinil
- Originator
- United Therapeutics Corporation
- Indication
- Interstitial Lung Disease ; Pulmonary Hypertension; Pulmonary Arterial Hypertension
- Approved Date
- 09/28/2023
- DS/DP
- 03/29/2028
Available intermediates
7 intermediates currently listed for Treprostinil. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| (1R,2R,3aS,9aS)-2,3,3a,4,9,9a-Hexahydro-1-[(3S)-3-hydroxyoctyl]-1H-benz[f]indene-2,5-diol | 101692-02-8 | / | / |
| 1-broMo-5-fluoro-2-Methyl-3-nitrobenzene | 502496-33-5 | / | / |
| methyl 4-cyclopropyl-2-fluorobenzoate | 1613413-65-2 | / | / |
| tert-butyl 2-(4-amino-6-chloropyrimidin-5-yloxy)ethylmethylcarbamate | 1787294-51-2 | / | / |
| 2H-Benz[f]inden-2-one, 9-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-3,3a,4,9-tetrahydro-5-methoxy-1-[(3S)-3-[(tetrahydro-2H-pyran-2-yl)oxy]octyl]-, (3aS,9R)- | 223734-60-9 | / | / |
| 2-allyl-3-methoxybenzaldehyde | 94956-98-6 | / | / |
| (5S)-1-Decyn-5-ol | 848609-05-2 | / | / |
Building toward Treprostinil?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →